UBXUnity Biotechnology, Inc.

Nasdaq unitybiotechnology.com


$ 1.62 $ -0.01 (-0.61 %)    

Thursday, 09-May-2024 13:05:56 EDT
QQQ $ 440.90 $ 0.44 (0.1 %)
DIA $ 393.12 $ 3.01 (0.77 %)
SPY $ 519.24 $ 1.80 (0.35 %)
TLT $ 90.52 $ 0.48 (0.53 %)
GLD $ 215.92 $ 1.22 (0.57 %)
$ 1.63
$ 1.62
$ 0.00 x 0
$ 0.00 x 0
$ 1.62 - $ 1.62
$ 1.46 - $ 3.82
17,172
na
24.08M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-15-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-15-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-23-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 07-31-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-11-2020 12-31-2019 10-K
18 11-06-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 03-06-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 06-07-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 visa-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-unity-biotechnology-lowers-price-target-to-8

HC Wainwright & Co. analyst Andrew Fein maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and lowers the price targe...

 hc-wainwright--co-maintains-buy-on-unity-biotechnology-lowers-price-target-to-8

HC Wainwright & Co. analyst Andrew Fein maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and lowers the price targe...

 unity-biotechnology-q4-2023-gaap-eps-028-may-not-be-comparable-to-077-estimate

Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(...

 unity-biotechnology-inc-announces-new-publication-in-nature-medicine-supports-therapeutic-potential-of-senolytics-to-provide-long-lasting-disease-modifying-intervention-in-vision-loss

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reve...

 unity-biotechnology--announced-that-the-first-patients-have-been-dosed-in-the-phase-2-aspire-study-of-ubx1325-a-bcl-xl-inhibitor-being-evaluated-head-to-head-against-standard-of-care-anti-vegf-in-patients-with-diabetic-macular-edema

ASPIRE is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UB...

 unity-biotechnology-upgraded---analyst-highlights-cash-strength--execution

Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc (NASDAQ: UBX) from Neutral to Outperform and

 wedbush-upgrades-unity-biotechnology-to-outperform

Wedbush analyst Andreas Argyrides upgrades Unity Biotechnology (NASDAQ:UBX) from Neutral to Outperform.

 hc-wainwright--co-reiterates-buy-on-unity-biotechnology-maintains-10-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:UBX) with a Buy and maintains $10 pr...

 unity-biotechnology-announces-48-week-results-from-phase-2-envision-study-of-ubx1325-in-patients-with-wet-age-related-macular-degeneration

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or rev...

 hc-wainwright--co-reiterates-buy-on-unity-biotechnology-maintains-10-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:UBX) with a Buy and maintains $10 pr...

 unity-biotechnology-q2-eps-085-beats-086-estimate

Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION